Please ensure Javascript is enabled for purposes of website accessibility

These 2 Stocks Are Cleaning Up Thanks To Medical Mask Sterilization. Are They Buys?

By Jim Halley – Jun 15, 2020 at 10:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Steris and Fortive are on the rise, thanks in part to their medical devices used to decontaminate N95 or N95-equivalent respirators.

Steris (STE 1.29%) and Fortive (FTV 3.02%) were the first companies to receive emergency use authorizations (EUAs) from the FDA to allow their medical devices to decontaminate N95 or N95-equivalent respirators for reuse.

Medical sterilization was already a growing business, but it has really taken off amid the coronavirus pandemic.

There are two reasons the market for medical device cleaning was already expected to rise at a compound growth rate of 5.75% through 2016: an aging population and an increased number of surgical procedures. The latter took a nosedive over the past few months because of coronavirus concerns -- but the same concerns helped buoy the share prices of Steris and Fortive.

Steris was at $165.40 on June 8, up 9% for the year, before falling along with the rest of the market on Thursday. In midday trading Friday, it was roughly even for the year. Fortive was at $62.98 at midday on Friday, roughly 17.5% down for the year, but still up 13.9% in the past month.

Fortive has had three consecutive years of revenue growth while Steris has had five. Both appear to be attractive investments. 

Medical personnel putting hands together.


The case for Fortive

Fortive, which spun off from Danaher (DHR 2.36%) in 2016, is a very diverse company, with more than 20 former companies under its umbrella. The portion of the Everett, Wash.-based business that is involved in medical sterilization is Advanced Sterilization Products (ASP), a former division of Johnson & Johnson (JNJ 0.86%) that Fortive purchased in 2019 for $2.7 billion.

Despite the greater demand for sterilization equipment because of COVID-19, the drop in elective surgical procedures during the shutdown kept revenue down for Fortive's ASP division, CEO Jim Lico said.

At ASP, we saw a significant drop in surgical procedure volume in China during Q1, upwards of 85% at the height of the COVID-19 response, but volume began to rebound by the end of March and continued into April. We expect the same pattern to play out in other geographies [as we have] seen elective procedures get delayed, and we likewise expect volumes to begin to normalize as soon as hospitals get to the other side of COVID-19 peaks and can begin to address the pent-up demand for these procedures.

In the first quarter, Fortive's sales were up 7.6% to $1.7 billion, driven in part by growth from its acquisitions. But the net earnings for the professional instrumentation and technologies business were down 74.5% to $41.9 million. The company said it was withdrawing its second-quarter and full-year guidance because of the uncertainties of the coronavirus pandemic.

Fortive kept its dividend at $0.07, the same as it has been since the company began in 2016. As management is still very much focused on growth, it probably won't be raising that dividend for awhile. That works out to a yield of 0.44% with a payout ratio of 8% over the trailing 12 months (TTM).

The case for Steris

Steris, like Fortive, has said it won't issue full-year guidance because of the pandemic. Unlike Fortis, this Mentor, Ohio, company is solely focused on infection prevention and procedural products. However, its fourth-quarter numbers were a pleasant surprise. 

Revenue grew 7% to $823 million, compared with $768.2 million in the same quarter in 2019, and that included a 14% rise in revenue for the company's applied sterilization technologies (AST) division. Net income also rose to $140.5 million, an increase of 7% year-over-year, and earnings per share rose to $1.64.

Steris CEO Walt Rosebrough said he sees considerable growth ahead for his company's AST division, in part because of the coronavirus.

We currently see continued growth in those AST facilities that process for pharma for PPE like gowns and gloves and for personal use medical devices for the home setting, like insulin pumps and blood glucose monitors. We have, however, begun to see declines in time-deferrable procedure-related devices like orthopedic implants. We expect this to be a relatively short-term phenomenon as healthcare providers begin doing these procedures again.

Steris also has a dividend, which it has raised for 10 consecutive years, including an 8.8% boost last year to $0.37, giving it a yield of 0.98% with a payout ratio of 26.2% (TTM), easily enough to cover the dividend.

For the short term, Steris is the obvious choice

I don't think either company is a bad choice for healthcare investors, as they both have solid records of growth over the past few years.

But Steris, even though it has less diversification than Fortive, seems to be handling the vagaries of the pandemic more effectively. It also looks poised for a greater jump once elective surgical procedures begin to pick back up. On top of that, its better dividend will reward patient investors.

Jim Halley owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Danaher Corporation Stock Quote
Danaher Corporation
$265.99 (2.36%) $6.13
Steris Plc Stock Quote
Steris Plc
$162.80 (1.29%) $2.08
Fortive Corporation Stock Quote
Fortive Corporation
$60.39 (3.02%) $1.77
Johnson & Johnson Stock Quote
Johnson & Johnson
$166.36 (0.86%) $1.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.